FDA Warns Lymol To Assess Talc Lead Risk Per ICH Q3D; Puts Others On Notice
Executive Summary
A warning letter to firm with legacy talc drug product puts pharmaceutical industry on notice: the US FDA expects applicants to meet requirements agency imposes post-approval for matters like elemental impurities compliance.